文献速递急性肾损伤肾小球疾病

C5aR与C5b-9通路在aHUS相关因子H突变小鼠中对肾TMA和大血管血栓的差异作用

Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
PubMed 文献 · Kidney Int · 2019-02-27

本研究在携带aHUS相关因子H点突变(小鼠W1206R,对应人W1183R)的FHR/R小鼠中,探讨C5aR与C5b-9通路对补体介导的TMA及大血管血栓的贡献。结果显示C5aR通路负责大血管血栓和慢性炎症损伤,C5b-9通路导致肾TMA,C5阻断比单独靶向任一通路更有效。

要点

  • C5aR通路驱动大血管血栓和慢性炎症损伤,不改善生存或肾TMA。
  • C5b-9通路导致肾TMA,改善生存但不预防大血管血栓。
  • C5阻断比选择性靶向C5aR或C5b-9通路更有效治疗aHUS。

核心结论

  • 在FHR/R小鼠中,C5aR通路负责大血管血栓和慢性炎症损伤,C5b-9通路导致肾TMA,C5阻断比单独靶向任一通路更有效。

研究设计与样本

  • 采用携带aHUS相关因子H点突变(小鼠W1206R,对应人W1183R)的FHR/R小鼠模型,通过C5缺陷、抗C5单抗治疗及C5aR1、C6、C9基因缺陷观察疾病表现。

主要发现

  • C5缺陷和抗C5单抗治疗阻断了FHR/R小鼠的所有疾病表现。
  • C5aR1基因缺陷预防了多器官大血管血栓,但未改善生存或减少肾TMA。
  • C6或C9缺陷显著改善生存并明显减少肾TMA,但未预防大血管血栓。
  • 老龄FHR/R C6-/-和FHR/R C9-/-小鼠出现类似C3肾小球肾炎的肾小球疾病。

临床怎么用

  • 对于aHUS,C5阻断可能比选择性靶向C5aR或C5b-9通路更有效。

局限性

  • 研究基于小鼠模型,结论外推至人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulated complement activation. Clinically, aHUS is effectively treated by an anti-C5 monoclonal antibody (mAb) but whether the disease is mediated by the C5a receptor (C5aR) or C5b-9 pathway, or both, is unknown. Here we address this in a factor H mutant mouse (FHR/R) which developed complement-mediated TMA as well as macrovascular thrombosis caused by an aHUS-related factor H point mutation (mouse W1206R, corresponding to human W1183R). C5 deficiency and anti-C5 mAb treatment blocked all disease manifestations in FHR/R mice. C5aR1 gene deficiency prevented macrovascular thrombosis in various organs but did not improve survival or reduce renal TMA. Conversely, C6 or C9 deficiency significantly improved survival and markedly diminished renal TMA but did not prevent macrovascular thrombosis. Interestingly, as they aged both FHR/R C6-/- and FHR/R C9-/- mice developed glomerular disease reminiscent of C3 glomerulonephritis. Thus, C5aR and C5b-9 pathways drove different aspects of disease in FHR/R mice with the C5aR pathway being responsible for macrovascular thrombosis and chronic inflammatory injury while the C5b-9 pathway caused renal TMA. Our data provide new understanding of the pathogenesis of complement-mediated TMA and macrovascular thrombosis in FHR/R mice and suggest that C5 blockade is more effective for the treatment of aHUS than selectively targeting the C5aR or C5b-9 pathway alone.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Ueda Y, Miwa T, Ito D, et al. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Kidney Int. 2019. PMID: 30910380. doi:10.1016/j.kint.2019.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。